Doz

Insulin degludec

انسولین دگلودک

⚠ Unverified

🍽️ Alimentary Tract And MetabolismUltra-long-acting basal insulin

🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:Use with caution 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA203314ATC A10AE06

Market / country: 🇺🇸 USA

Tresiba (US)

🧮 Dose calculator

Type 2 diabetes mellitus · Regimen source: FDA Tresiba · 2.3

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

  • ⛔ During episodes of hypoglycaemia; hypersensitivity to the insulin or its excipients. FDA Tresiba · 4

Warnings

Formulations

  • 100 units/mL (U-100) FlexTouch pen or vial — injection 🇺🇸 USA FDA Tresiba · 3
  • 200 units/mL (U-200) FlexTouch pen — injection 🇺🇸 USA FDA Tresiba · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Tresiba · 8.1

    “Risk Summary Available data from one unpublished trial and the published literature with TRESIBA use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Tresiba · 8.2

    “Risk Summary There are no data on the presence of insulin degludec in human milk, the effects on the breastfed infant, or the effects on milk production.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tresiba · 8.4

    “The safety and effectiveness of TRESIBA to improve glycemic control in pediatric patients 1 year of age and older with diabetes mellitus have been established.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tresiba · 8.5

    “In controlled clinical trials [see Clinical Studies ( 14 )] a total of 77 (7%) of the 1102 TRESIBA-treated patients with type 1 diabetes were 65 years or older and 9 (1%) were 75 years or older.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav